文献速递主动脉疾病

复杂主动脉瘤开窗/分支EVAR与开放手术2年成本效果比较

Editor's Choice - A Study of the Cost-effectiveness of Fenestrated/branched EVAR Compared with Open Surgery for Patients with Complex Aortic Aneurysms at 2 Years.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-01-17

本研究比较开窗/分支支架(f/b EVAR)与开放手术(OSR)治疗胸腹或复杂腹主动脉瘤的2年成本效果。f/b EVAR组来自法国WINDOW前瞻性多中心注册,OSR组取自法国国家住院出院数据库,倾向匹配后比较死亡、再入院与住院费用。2年死亡率无显著差异,但f/b EVAR费用更高且再入院更多,除膈上胸腹主动脉瘤亚组外均属劣势策略。

要点

  • 2年死亡率f/b EVAR 14.9%与OSR 11.8%无显著差异(p=.150)。
  • f/b EVAR两年住院费用€46,039,高于OSR的€22,779(p<.001)。
  • 除膈上胸腹主动脉瘤亚组外,f/b EVAR均为费用更高且效果不更优的劣势策略。

核心结论

  • 在高危患者中,f/b EVAR的2年死亡率与较低危患者接受OSR相当,但费用更高。
  • 费用主要由支架移植物成本驱动,未被更低的医疗资源消耗所抵消。
  • 除膈上胸腹主动脉瘤亚组外,f/b EVAR在2年时均为劣势策略(费用更高且效果更差)。

研究设计与样本

  • 比较性研究:两组匹配的胸腹主动脉瘤或复杂腹主动脉瘤患者,随访2年。
  • f/b EVAR组为纳入法国WINDOW多中心前瞻性注册的患者,共268例高危患者。
  • OSR组从法国国家住院出院数据库提取,为同期1678例平均或低危患者。
  • 采用单/多因素Cox回归分析治疗与2年死亡率的关联。
  • 按肾旁/近肾腹主动脉瘤、膈下及膈上胸腹主动脉瘤估算增量成本效果比(ICER)。

主要发现

  • 2年死亡率f/b EVAR组14.9%,OSR组11.8%,差异无统计学意义(p=.150)。
  • 多因素Cox回归未发现2年死亡率与治疗方式存在关联。
  • 至少一次再入院比例相似(f/b EVAR 69.7% vs OSR 64.2%,p=.096)。
  • f/b EVAR组平均再入院次数更多(2.2次 vs 1.7次,p=.001)。
  • 2年住院费用f/b EVAR组更高(€46,039 vs €22,779,p<.001)。

关键数值与推荐

  • 膈上胸腹主动脉瘤亚组ICER为每避免一例死亡€42,195,800。
  • 其余亚组(肾旁/近肾腹主动脉瘤及膈下胸腹主动脉瘤)f/b EVAR均为劣势策略。

临床怎么用

  • 对高危复杂主动脉瘤患者,f/b EVAR可考虑用于降低开放手术风险,但需权衡其更高费用与再入院负担。
  • 支架移植物成本是费用差异的主要来源,决策时应结合患者风险分层与卫生经济学评估。
  • 膈上胸腹主动脉瘤亚组虽ICER极高,仍可视为唯一未显示劣势的亚组,需个体化讨论。

局限性

  • f/b EVAR组为高危患者,OSR组为平均或低危患者,两组风险构成不同,非随机比较。
  • OSR数据来自行政数据库,可能存在未测量混杂与信息偏倚。
  • 随访仅2年,未能反映长期成本效果。
  • 作者指出尚需在低危f/b EVAR患者中进一步评估成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim was to assess the cost-effectiveness of fenestrated and branched stent grafts (f/b EVAR) compared with open surgical repair (OSR) in thoraco-abdominal or complex abdominal aortic aneurysms (TAAA/AAA) at 2 years. METHODS: Two matched cohorts of patients with TAAA or complex AAA were compared after a follow-up of two years. Patients included in the WINDOW French multicentre prospective registry were treated by f/b EVAR, and OSR patients were extracted from the French national hospital discharge database. All cause mortality was assessed along with readmissions and hospital costs. The association between treatment and 2 year mortality was assessed by uni/multivariate Cox regression analyses using pre- and post-operative characteristics. Incremental cost-effectiveness ratios (ICER) were estimated for para/juxtarenal AAA, and infra- and supra-diaphragmatic TAAA. RESULTS: A total of 268 high risk patients were treated by f/b EVAR and 1678 average or low risk patients were treated with OSR during the same period. Mortality did not significantly differ between the groups (14.9% vs. 11.8%, p = .150) and multivariate Cox regressions did not find an association between 2 year mortality and treatment. Similar proportions of patients were readmitted at least once (69.7% with f/b EVAR vs. 64.2% with OSR, p = .096) but f/b EVAR patients had more readmissions on average (2.2 vs. 1.7, p = .001). Two year hospital costs were higher in the f/b EVAR group (€46,039 vs. €22,779, p < .001). At 2 years, f/b EVAR was dominated (more expensive and less effective), except in the supra-diaphragmatic TAAA subgroup with an ICER of €42,195,800 per death averted. CONCLUSIONS: f/b EVAR in high risk patients offers similar 2 year mortality to OSR performed in lower risk patients but at a higher cost. The cost is mainly driven by the cost of the stent graft, which is not compensated for by lower healthcare resource consumption. Further studies are necessary to evaluate the cost-effectiveness in low risk f/b EVAR patients who may experience fewer complications.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Michel M, Becquemin JP, Marzelle J, et al. Editor's Choice - A Study of the Cost-effectiveness of Fenestrated/branched EVAR Compared with Open Surgery for Patients with Complex Aortic Aneurysms at 2 Years. Eur J Vasc Endovasc Surg. 2018. PMID: 29342417. doi:10.1016/j.ejvs.2017.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。